Mamta Behl, M.S, Ph.D, D.A.B.T, explores the latest developments in neurotoxicity models. This method uses a combination of in vitro, in vivo extrapolation, and exposure assessment to rapidly screen compounds with neurotoxic potential and disseminate information in a timely manner for public health. What you’ll learn:
- A survey of the promising in vitro neurotoxic models
- How well these models have performed
- Use of these models for screening and regulatory submission
About our Speaker:
Mamta Behl, M.S, Ph.D., D.A.B.T. currently leads the Development Neurotoxicity health Effects Innovation Program at the NTP, a high-priority initiative designed to improve testing of environmental compounds with unknown DNT potential thereby addressing concerns that environmental factors may contribute to the global rise in neurodevelopmental disorders. She also serves in a dual capacity as a non-clinical senior toxicology lead to design, analyze and interpret studies via co-coordination with teams of scientists at the NTP in the disciplines of reproductive toxicology, carcinogenesis, inhalation toxicology, genetic toxicology, pathology, statistics, chemistry, ADME, molecular biology and bioinformatics, and publishes findings as NTP technical reports and papers in scientific journals with a goal to provide data for use in regulatory decision-making.
Behl received a B.S. in pharmaceutical sciences from the University of Mumbai, India: M.S. in Psychological Sciences (learning and memory) and Ph.D. in Neurotoxicology from Purdue University.
The potential for developmental neurotoxicity of environmental chemicals remains a high public priority due to concerns that recent increases in the prevalence of neurological disorders (e.g. ADHD, Autism) in children may in part be due to chemical effects. Currently, it takes over a decade for regulations to be put into effect from the time a compound is identified as potentially neurotoxic due to the rigor required for decision- making. This talk addresses some latest developments in the use of in vitro, alternate animal models and automated behavior using artificial intelligence in combination with in vitro in vivo extrapolation methods and exposure assessment to rapidly screen compounds with neurotoxic potential and disseminate information in a timely manner for protection of public health.
ScitoVation helps clients assess chemical compound safety using innovative science, next-generation technology, and professional expertise. ScitoVation is known for partnership, flexibility, and proven success in its work to develop safer and more effective pharmaceuticals, food ingredients, agricultural chemicals, commodity chemicals and consumer products. A spin-off of the former The CIIT and The Hammer Institutes for Chemical & Drug Safety Sciences, ScitoVation is an industry leader of New Approach Methods (NAMS) for chemical/drug discovery & development in the rapidly evolving global regulatory landscape.